← Browse by Condition

Medical Condition

parkinson disease

Total Trials

45

Recruiting Now

45

Trial Phases

Phase 2, Phase 1

Parkinson's disease research has expanded from symptomatic management (dopaminergic drugs, DBS) toward neuroprotective and disease-modifying strategies targeting alpha-synuclein aggregation β€” the protein implicated in Lewy body pathology. Prodromal biomarker studies now aim to identify patients years before motor symptoms appear, when intervention may be most effective.

Trials test alpha-synuclein antibodies (prasinezumab, cinpanemab), GBA1 gene therapy, adaptive deep brain stimulation (aDBS), GLP-1 agonists (liraglutide, semaglutide), and nilotinib for neuroprotection. Skin biopsy and cerebrospinal fluid alpha-synuclein assays are emerging as enrollment biomarkers.

Disease-modifying trials often restrict enrollment to early-stage patients (Hoehn & Yahr 1β€“2.5) within a few years of diagnosis to capture sufficient disease duration for benefit detection.

Frequently Asked Questions — parkinson disease Clinical Trials

How many clinical trials are currently recruiting for parkinson disease?

ClinicalMetric currently tracks 45 actively recruiting clinical trials for parkinson disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 45. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for parkinson disease?

parkinson disease research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a parkinson disease clinical trial?

Eligibility criteria for parkinson disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

1

Phase 2

2

Top Sponsors

National Taiwan University Hospital 3 trials

IRCCS San Raffaele 2 trials

Xiangya Hospital of Central South University 2 trials

University Hospital, Toulouse 2 trials

Chinese PLA General Hospital 1 trial

Recruiting Clinical Trials

VIM+PTT MRgFUS for PD

Chinese PLA General Hospital

Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease

Centre hospitalier de l'Univer...

Evaluation of the Safety of Electrical Spinal Cord Stimulation in Parkinson's Patients Presenting With Painful Camptocormia

University Hospital, Rouen

Cognitive Decline Following Deep Brain Stimulation

Medical University of South Ca...

Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

Amsterdam UMC, location VUmc

Exploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease

Heidelberg University

Neurophysiology of Reward Signaling in Parkinson's Disease

Vanderbilt University Medical ...

High-intensity Functional Training on Functional and Cognitive Performance in People with Parkinson's Disease.

Fundacion Para La Investigacio...

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

United States, Austr...

Abbott Medical Devices

NCT07001150 Phase 2

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Tanta University

rTMS as an Intervention for Levodopa-induced Dyskinesia

Danish Research Centre for Mag...

Light Therapy in Parkinson's Disease

Second Affiliated Hospital of ...

TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD

United States, Brazi...

Oregon Health and Science Univ...

Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology

IRCCS San Raffaele

Social & QoL Behaviors in Parkinson's Disease

Gregory Wallace

Visuomotor Control in Parkinson Disease

National Taiwan University Hos...

Effect of a Vibrating Therapy Ball on Tremor and Daily Activities in Patients With Different Tremor Syndroms

Parkinson's Clinic in Beelitz-...

Cognitive Testing Online in Parkinson's Disease

McGill University

Longitudinal Investigation of I2BS in PD

University of Exeter

University of Delaware Parkinson's Disease Registry

University of Delaware

Gait Control in Parkinson Disease

Université Catholique de Louva...

Chinese PD Registry

Xiangya Hospital of Central So...

Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)

University Hospital, Toulouse

REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis

Czechia, Switzerland

Insel Gruppe AG, University Ho...

Detection of Internal Tremors by Oscillometry in Parkinson's Patient

University Hospital, Toulouse

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

United States, Nethe...

Radboud University Medical Cen...

Influence of Autonomy on Motor Learning in People With Parkinson's Disease

National Taiwan University Hos...

Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

Tianjin Medical University

Intestinal Immunity in Neurologic Disease

Yale University

Real-Time Levodopa Level Monitoring in Parkinson Disease

University of California, San ...

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

University of Texas Southweste...

Clinical Outcomes for Deep Brain Stimulation

Washington University School o...

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

United States, Belgi...

Boston Scientific Corporation

NCT06680830 Phase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

United States, Israe...

Cognitive-motor Training in Parkinson Disease

National Yang Ming Chiao Tung ...

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

IRCCS San Raffaele

Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms

Istituti Clinici Scientifici M...

Chinese PD-LRRK2 Registry

Xiangya Hospital of Central So...

Physical Activity on Neuroinflammation in Parkinson's Disease

IRCCS National Neurological In...

Superior Cervical Ganglion in Parkinson's Disease

Fondazione Policlinico Univers...

The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease

University of Aarhus

Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life

Centre Hospitalier Régional d'...

Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease

Turkey (Türkiye)

Acibadem University

Application of Thoracic Epidural SCS for Managing FOG in Patients With Advanced Parkinson's Disease

National Taiwan University Hos...

NCT04246437 Phase 1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Daniel Claassen

Related Conditions

essential tremor (3) dystonia (3) multiple system atrophy (3) movement disorders (2) rem sleep behavior disorder (2) neurodegenerative diseases (2) multiple sclerosis (2) healthy (1) parkinsonian syndromes (1) tremor (1) primary dystonia (1) secondary dystonia (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology